Corgenix Medical Corporation (OTC BB: CONX), in partnership with Tulane University, the U.S. Army Medical Research Institute of Infectious Diseases (USAMRIID) and two corporate partners, will develop and manufacture improved diagnostic tests for viral hemorrhagic fevers under a $3.8 million grant awarded by the National Institutes of Health (NIH).
